1. Roberts DM, Ostapchuk M, O brien JG. Infantile colic. Am Fam Physician 2004;70:735–40.
4. Pärtty A, Lehtonen L, Kalliomäki M, Salminen S, Isolauri E. Probiotic
Lactobacillus rhamnosus GG therapy and microbiological programming in infantile colic: a randomized, controlled trial. Pediatr Res 2015;78:470.
7. Leung AKC, Lemay JF. Infantile colic: a review. J R Soc Promot Health 2004;124:162–6.
8. Romanello S, Spiri D, Marcuzzi E, Zanin A, Boizeau P, Riviere S, et al. Association between childhood migraine and history of infantile colic. JAMA 2013;309:1607–12.
9. Savino F, Tarasco V. New treatments for infant colic. Curr Opin Pediatr 2010;22:791–7.
10. Savino F, Clara Grassino E, Guidi C, Oggero R, Silvestro L, Miniero R. Ghrelin and motilin concentration in colicky infants. Acta Paediatr 2006;95:738–41.
11. Pärtty A, Kalliomäki M, Salminen S, Isolauri E. Infantile colic is associated with low-grade systemic inflammation. J Pediatr Gastroenterol Nutr 2017;64:691–5.
14. Danielsson B, Hwang CP. Treatment of infantile colic with surface active substance (simethicone). Acta Paediatr Scand 1985;74:446–50.
16. Goldman MH. Dicycloverine for persistent crying in babies: dicycloverine is contraindicated in infants. BMJ 2004;328:956–7.
17. Biagioli E, Tarasco V, Lingua C, Moja L, Savino F. Pain-relieving agents for infantile colic. Cochrane Database Syst Rev 2016;9:CD009999.
19. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 1995;125:1401–2.
20. Soccol CR, Vandenberghe LPdS, Spier MR, Medeiros ABP, Yamaguishi CT, Lindner JDD, et al. The potential of probiotics: a review. Food Technol Biotech 2010;48:413–34.
21. Lin YP, Thibodeaux CH, Peña JA, Ferry GD, Versalovic J. Probiotic
Lactobacillus reuteri suppress proinflammatory cytokines via c-Jun. Inflamm Bowel Dis 2008;14:1068–83.
22. Bashashati M, Rezaei N, Shafieyoun A, McKernan DP, Chang L, Öhman L, et al. Cytokine imbalance in irritable bowel syndrome: a systematic review and meta-analysis. Neurogastroenterol Motil 2014;26:1036–48.
23. Pike BL, Paden KA, Alcala AN, Jaep KM, Gormley RP, Maue AC, et al. Immunological biomarkers in postinfectious irritable bowel syndrome. J Travel Med 2015;22:242–50.
25. Rhoads JM, Fatheree NY, Norori J, Liu Y, Lucke JF, Tyson JE, et al. Altered fecal microflora and increased fecal calprotectin in infants with colic. J Pediatr 2009;155:823–8.e821.
26. Savino F, Garro M, Montanari P, Galliano I, Bergallo M. Crying time and RORγ/FOXP3 expression in
Lactobacillus reuteri DSM17938-treated infants with colic: a randomized trial. J Pediatr 2018;192:171–7.e171.
27. Kim CH. FOXP3 and its role in the immune system. Adv Exp Med Biol 2009;665:17–29.
28. Kianifar H, Ahanchian H, Grover Z, Jafari S, Noorbakhsh Z, Khakshour A, et al. Synbiotic in the management of infantile colic: a randomised controlled trial. J Paediatr Child Health 2014;50:801–5.
29. Mi GL, Zhao L, Qiao DD, Kang WQ, Tang MQ, Xu JK. Effectiveness of
Lactobacillus reuteri in infantile colic and colicky induced maternal depression: a prospective single blind randomized trial. Antonie Van Leeuwenhoek 2015;107:1547–53.
30. Savino F, Galliano I, Savino A, Daprà V, Montanari P, Calvi C, et al.
Lactobacillus reuteri DSM 17938 probiotics may increase CC-chemokine receptor 7 expression in infants treated with for colic. Front Pediatr 2019;7:1–7.
31. Gerasimov S, Gantzel J, Dementieva N, Schevchenko O, Tsitsura O, Guta N, et al. Role of
Lactobacillus rhamnosus (FloraActive™) 19070-2 and
Lactobacillus reuteri (FloraActive™) 12246 in infant colic: a randomized dietary study. Nutrients 2018;10:1975.
32. Sung V, Hiscock H, Tang ML, Mensah FK, Nation ML, Satzke C, et al. Treating infant colic with the probiotic
Lactobacillus reuteri: double blind, placebo controlled randomised trial. BMJ 2014;348:g2107.
33. Ashraf MW, Ayaz SB, Ashraf MN, Matee S, Shoaib M. Probiotics are effective in alleviating infantile colic; results of a randomized controlled trial held at Benazir Bhutto hospital, Rawalpindi, Pakistan. RMJ 2015;40:277–80.
34. Giglione E, Prodam F, Bellone S, Monticone S, Beux S, Marolda A, et al. The association of
Bifidobacterium breve BR03 and B632 is effective to prevent colics in bottle-fed infants: a pilot, controlled, randomized, and double-blind study. J Clin Gastroenterol 2016;50:S164–7.
37. Skonieczna-Żydecka K, Janda K, Kaczmarczyk M, Marlicz W, Łoniewski I, Łoniewska B. The effect of probiotics on symptoms, gut microbiota and inflammatory markers in infantile colic: a systematic review, meta-analysis and meta-regression of randomized controlled trials. J Clin Med 2020;9:1–21.
38. Xu M, Wang J, Wang N, Sun F, Wang L, Liu XH. The efficacy and safety of the probiotic bacterium
Lactobacillus reuteri DSM 17938 for infantile colic: a meta-analysis of randomized controlled trials. PLoS One 2015;10:e0141445.
39. Sung V, Collett S, de Gooyer T, Hiscock H, Tang M, Wake M. Probiotics to prevent or treat excessive infant crying: systematic review and meta-analysis. JAMA Pediatrics 2013;167:1150–7.
40. Gutiérrez-Castrellón P, Indrio F, Bolio-Galvis A, Jiménez-Gutiérrez C, Jimenez-Escobar I, López-Velázquez G. Efficacy of
Lactobacillus reuteri DSM 17938 for infantile colic: systematic review with network meta-analysis. Medicine 2017;96:e9375–5.
41. Rahimi VB, Askari VR, Shirazinia R, Soheili-Far S, Askari N, RahmanianDevin P, et al. Protective effects of hydro-ethanolic extract of Terminalia chebula on primary microglia cells and their polarization (M1/M2 balance). Mult Scler Relat Disord 2018;25:5–13.
43. Fatheree NY, Liu Y, Ferris M, Van Arsdall M, McMurtry V, Zozaya M, et al. Hypoallergenic formula with
Lactobacillus rhamnosus GG for babies with colic: a pilot study of recruitment, retention, and fecal biomarkers. World J Gastrointest Pathophysiol 2016;7:160–70.
45. Olafsdottir E, Aksnes L, Fluge G, Berstad A. Faecal calprotectin levels in infants with infantile colic, healthy infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children. Acta Paediatrica 2002;91:45–50.
46. Sung V, Cabana MD. Probiotics for colic—is the gut responsible for infant crying after all? J Pediatr 2017;191:6–8.
47. Røseth A, Fagerhol M, Aadland E, Schjønsby H. Assessment of the neutrophil dominating protein calprotectin in feces: a methodologic study. Scand J Gastroenterol 1992;27:793–8.
48. Røseth AG, Aadland E, Jahnsen J, Raknerud N. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997;58:176–80.
49. Røseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 1999;34:50–4.
50. Berstad A, Arslan G, Folvik G. Relationship between intestinal permeability and calprotectin concentration in gut lavage fluid. Scand J Gastroenterol 2000;35:64–9.
51. Lothe L, Lindberg T, Jakobsson I. Macromolecular absorption in infants with infantile colic. Acta Pædiatrica 1990;79:417–21.
52. Michielan A, D’Incà R. Intestinal permeability in inflammatory bowel disease:pathogenesis, clinical evaluation, and therapy of leaky gut. Mediators Inflamm 2015;2015:1–11.
54. Hietbrink F, Besselink MGH, Renooij W, de Smet MBM, Draisma A, van der Hoeven H, et al. Systemic inflammation increases intestinal permeability during experimental human endotoxemia. Shock 2009;32:374–8.
56. Xu LL, Warren MK, Rose WL, Gong W, Wang JM. Human recombinant monocyte chemotactic protein and other C-C chemokines bind and induce directional migration of dendritic cells in vitro. J Leukoc Biol 1996;60:365–71.
57. Maurer M, von Stebut E. Macrophage inflammatory protein-1. Int J Biochem Cell Biol 2004;36:1882–6.
59. Xiao TS. Innate immunity and inflammation. Cell Mol Immunol 2017;14:1–3.
60. Geremia A, Biancheri P, Allan P, Corazza GR, Di Sabatino A. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev 2014;13:3–10.
61. Jones SE, Versalovic J. Probiotic
Lactobacillus reuteribiofilms produce antimicrobial and anti-inflammatory factors. BMC Microbiol 2009;9:35. 1-9.
62. Fallahi G, Motamed F, Yousefi A, Shafieyoun A, Najafi M, Khodadad A, et al. The effect of probiotics on fecal calprotectin in patients with cystic fibrosis. Turk J Pediatr 2013;55:475–8.
63. Lai HH, Chiu CH, Kong MS, Chang CJ, Chen CC. Probiotic
Lactobacillus casei: effective for managing childhood diarrhea by altering gut microbiota and attenuating fecal inflammatory markers. Nutrients 2019;11:1150.
64. Santas J, Fuentes MC, Tormo R, Guayta-Escolies R, Lázaro E, Cuñé J. Pediococcus pentosaceus CECT 8330 and Bifidobacterium longum CECT 7894 show a trend towards lowering infantile excessive crying syndrome in a pilot clinical trial. Int J Pharm Bio Sci 2015;6:458–66.
65. Couper KN, Blount DG, Riley EM. IL-10: the master regulator of immunity to infection. J Immunol 2008;180:5771.
66. Liu Y, Fatheree NY, Dingle BM, Tran DQ, Rhoads JM.
Lactobacillus reuteri DSM 17938 changes the frequency of Foxp3+ regulatory T cells in the intestine and mesenteric lymph node in experimental necrotizing enterocolitis. PLoS One 2013;8:e56547.
67. Tran DQ, Ramsey H, Shevach EM. Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood 2007;110:2983–90.
70. Liu Y, Fatheree NY, Mangalat N, Rhoads JM. Human-derived probiotic
Lactobacillus reuteri strains differentially reduce intestinal inflammation. Am J Physiol Gastrointest Liver Physiol 2010;299:G1087–96.
71. Rahimi VB, Shirazinia R, Fereydouni N, Zamani P, Darroudi S, Sahebkar AH, et al. Comparison of honey and dextrose solution on post-operative peritoneal adhesion in rat model. Biomed Pharmacother 2017;92:849–55.
72. Mannon P, Reinisch W. Interleukin 13 and its role in gut defence and inflammation. Gut 2012;61:1765–73.
73. Van Kampen C, Gauldie J, Collins S. Proinflammatory properties of IL-4 in the intestinal microenvironment. Am J Physiol Gastrointest Liver Physiol 2005;288:G111–7.
75. Scully P, MacSharry J, O’Mahony D, Lyons A, O’Brien F, Murphy S, et al.
Bifidobacterium infantis suppression of Peyer’s patch MIP-1α and MIP-1β secretion during Salmonella infection correlates with increased local CD4+CD25+ T cell numbers. Cell Immunol 2013;281:134–40.
76. Vemuri R, Gundamaraju R, Shinde T, Perera AP, Basheer W, Southam B, et al.
Lactobacillus acidophilus DDS-1 modulates intestinal-specific microbiota, short-chain fatty acid and immunological profiles in aging mice. Nutrients 2019;11:1–23.
77. Liu Y, Fatheree NY, Mangalat N, Rhoads JM.
Lactobacillus reuteri strains reduce incidence and severity of experimental necrotizing enterocolitis via modulation of TLR4 and NF-κB signaling in the intestine. Am J Physiol Gastrointest Liver Physiol 2012;302:G608–17.
78. Peña JA, Li SY, Wilson PH, Thibodeau SA, Szary AJ, Versalovic J. Genotypic and phenotypic studies of murine intestinal lactobacilli: species differences in mice with and without colitis. Appl Environ Microbiol 2004;70:558–68.
79. Ma D, Forsythe P, Bienenstock J. Live
Lactobacillus rhamnosus [corrected] is essential for the inhibitory effect on tumor necrosis factor alpha-induced interleukin-8 expression. Infect Immun 2004;72:5308–14.
80. Madsen KL, Doyle JS, Jewell LD, Tavernini MM, Fedorak RN.
Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999;116:1107–14.
81. Bull MJ, Plummer NT. Part 1: the human gut microbiome in health and disease. Integr Med (Encinitas) 2014;13:17–22.
82. Dubois NE, Gregory KE. Characterizing the intestinal microbiome in infantile colic: findings based on an integrative review of the literature. Biol Res Nurs 2015;18:307–15.
87. Gagliardi A, Totino V, Cacciotti F, Iebba V, Neroni B, Bonfiglio G, et al. Rebuilding the gut microbiota ecosystem. Int J Environ Res Public Health 2018;15:1–24.
88. Kumar R, Sood U, Gupta V, Singh M, Scaria J, Lal R. Recent advancements in the development of modern probiotics for restoring human gut microbiome dysbiosis. Indian J Microbiol 2020;60:12–25.
89. Savino F, De Marco A, Ceratto S, Mostert M. Fecal calprotectin during treatment of severe infantile colic with
Lactobacillus reuteri DSM 17938: a randomized, double-blind, placebo-controlled trial. Pediatrics 2015;135(Supplement 1): S5–6.
90. Mu Q, Tavella VJ, Luo XM. Role of
Lactobacillus reuteri in human health and diseases. Front Microbiol 2018;9:757.
91. Mohan R, Koebnick C, Schildt J, Mueller M, Radke M, Blaut M. Effects of
Bifidobacterium lactis Bb12 supplementation on body weight, fecal pH, acetate, lactate, calprotectin, and IgA in preterm infants. Pediatr Res 2008;64:418–22.
92. Bailey JR, Vince V, Williams NA, Cogan TA. Streptococcus thermophilus NCIMB 41856 ameliorates signs of colitis in an animal model of inflammatory bowel disease. Benef Microbes 2017;8:605–14.
93. Klemenak M, Dolinšek J, Langerholc T, Di Gioia D, Mičetić-Turk D. Administration of
Bifidobacterium breve Decreases the Production of TNF-α in Children with Celiac Disease. Dig Dis Sci 2015;60:3386–92.
94. Kumar M, Hemalatha R, Nagpal R, Singh B, Parasannanavar D, Verma V, et al. Probiotic approaches for targeting inflammatory bowel disease: an update on advances and opportunities in managing the disease. Int J Probiotics Prebiotics 2016;11:99–116.
95. Madsen KL. Inflammatory bowel disease: lessons from the IL-10 gene-deficient mouse. Clin Invest Med 2001;24:250–7.
96. Ekhlasi G, Zarrati M, Agah S, Hosseini AF, Hosseini S, Shidfar S, et al. Effects of symbiotic and vitamin E supplementation on blood pressure, nitric oxide and inflammatory factors in non-alcoholic fatty liver disease. EXCLI J 2017;16:278–90.